Email this article 
Correlation of p53 Expression with Histopathological Grading and Myometrial Invasion in Endometrioid Endometrial Carcinoma
Abstract
Endometrioid endometrial carcinoma (EEC) is commonly assessed using histopathological grade and myometrial invasion, while p53 expression may provide complementary molecular information. This study aimed to assess the correlation of p53 expression with histopathological grade and myometrial invasion in EEC. This retrospective analytic observational study included 60 hysterectomy specimens diagnosed as EEC at Dr. Saiful Anwar General Hospital, Malang, during 2022–2025. p53 expression was evaluated by immunohistochemistry and classified as wild-type or abnormal. Associations were analyzed using Fisher’s exact test and correlations using Spearman’s test. p53-abnormal expression was identified in 13.3% of cases and was more frequent in high-grade than low-grade EEC (21.4% vs. 6.3%; OR=4.09; p=0.130) and in tumors with myometrial invasion >=50% than <50% (20.0% vs. 4.0%; OR=6.00; p=0.123). Correlations with histopathological grade (ro=0.223; p=0.131) and myometrial invasion (ro=0.232; p=0.124) were weak and not statistically significant. Although no significant associations or correlations were found, p53 immunohistochemistry may provide additional biological information after histopathological diagnosis, particularly where access to comprehensive molecular testing is limited. Integrating p53 status with histopathological, clinicopathological, and other molecular parameters may support more comprehensive EEC risk stratification and potentially help optimize patient management within resource-limited clinical settings and tertiary referral hospitals.
Keywords
Full Text:
PDFReferences
Arciuolo, D., Travaglino, A., Raffone, A., Raimondo, D., Santoro, A., Russo, D., Varricchio, S., Casadio, P., Inzani, F., Seracchioli, R., Mollo, A., Mascolo, M., & Zannoni, G. F. (2022). TCGA molecular prognostic groups of endometrial carcinoma: Current knowledge and future perspectives. International Journal of Molecular Sciences, 23(19), 11684. https://doi.org/10.3390/ijms231911684
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. https://doi.org/10.3322/caac.21834
Casanova, J., da Costa, A. G., Lopes, A. P., Catarino, A., Nave, M., Sousa, A. C., & Lima, J. (2024). Molecular classification of endometrial cancer: Preliminary experience from a single Portuguese academic center. Pathology and Oncology Research, 30, 1611835. https://doi.org/10.3389/pore.2024.1611835
Chandra, L., Agus, S., & Sulaini, P. (2019). Peran imunoekspresi Bcl-2 pada derajat histopatologik dan kedalaman invasi miometrium pada karsinoma endometrium tipe I. Majalah Patologi Indonesia, 28(1), 10–16.
Chang, Y. W., Kuo, H. L., Chen, T. C., Chen, J., Lim, L., Wang, K. L., & Chen, J. R. (2024). Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: A retrospective single-institute study. Journal of Gynecologic Oncology, 35(6), e78. https://doi.org/10.3802/jgo.2024.35.e78
Clarke, M. A., Wentzensen, N., Köbel, M., Erickson, B. K., Wijayabahu, A. T., Kahn, A. G., Toboni, M. D., Arend, R. C., & Pfeiffer, R. M. (2025). Age-specific incidence and five-year relative survival of endometrial cancer histotypes by race and ethnicity among US women, 2000 to 2019. Gynecologic Oncology, 200, 137–144. https://doi.org/10.1016/j.ygyno.2025.07.011
Concin, N., et al. (2025). ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: Update 2025. The Lancet Oncology, 26(8), e423–e435. https://doi.org/10.1016/S1470-2045(25)00167-6
Erfiandi, F., Balqis, S. A. A., Salima, S., Mantilidewi, K. I., Kurniadi, A., & Wibowo, V. D. (2023). Gambaran faktor risiko kanker endometrium di RSUP Dr. Hasan Sadikin pada tahun 2020–2022. Indonesian Journal of Obstetrics & Gynecology Science, 6(3), 452–459. https://doi.org/10.24198/obgynia.v6i3.578
Himpunan Onkologi Ginekologi Indonesia. (2018). Pedoman Nasional Pelayanan Kedokteran Kanker Ginekologi. HOGI/POGI.
Jamieson, A., et al. (2023). Clinical behavior and molecular landscape of stage I p53-abnormal low-grade endometrioid endometrial carcinomas. Clinical Cancer Research, 29(23), 4949–4957. https://doi.org/10.1158/1078-0432.CCR-23-1397
Kementerian Kesehatan Indonesia. (2021). Epidemiologi Kanker Endometrium Indonesia 2000–2019.
Köbel, M., Ronnett, B. M., Singh, N., Soslow, R. A., Gilks, C. B., & McCluggage, W. G. (2019). Interpretation of p53 immunohistochemistry in endometrial carcinomas: Toward increased reproducibility. International Journal of Gynecological Pathology, 38(Suppl. 1), S123–S131. https://doi.org/10.1097/PGP.0000000000000488
Meijs-Hermanns, P., et al. (2025). Improving pre-operative binary grading: Relevance of p53 and PR expression in grade 2 endometrioid endometrial carcinoma. International Journal of Gynecological Cancer, 35(4), 101682. https://doi.org/10.1016/j.ijgc.2025.101682
Memon, A., Bannister, P., Edensor, S., & Tattan, M. (2022). Endometrial cancer: Current epidemiology, detection, and management. Nova Science Publishers.
Nakamura, M., Obata, T., Daikoku, T., & Fujiwara, H. (2019). The association and significance of p53 in gynecologic cancers: The potential of targeted therapy. International Journal of Molecular Sciences, 20(21), 5482. https://doi.org/10.3390/ijms20215482
Singh, N., Piskorz, A. M., Bosse, T., Jimenez-Linan, M., Rous, B., Brenton, J. D., Gilks, C. B., & Köbel, M. (2020). p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. The Journal of Pathology, 250(3), 336–345. https://doi.org/10.1002/path.5375
Sofyan, N., Sudiana, I. K., & Askandar, B. (2020). Profile of endometrial cancer patients in the third referral hospital in Surabaya based on known risk factors. Biomolecular and Health Science Journal, 3(2), 66. https://doi.org/10.20473/bhsj.v3i2.22141
Stavropoulos, A., Varras, M., Vasilakaki, T., Varra, V. K., Tsavari, A., Varra, F. N., Nonni, A., Kavantzas, N., & Lazaris, A. C. (2019). Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression. Oncology Letters, 17(5), 4575–4589. https://doi.org/10.3892/ol.2019.10093
Vermij, L., et al. (2022). p53 immunohistochemistry in endometrial cancer: Clinical and molecular correlates in the PORTEC-3 trial. Modern Pathology, 35(10), 1475–1483. https://doi.org/10.1038/s41379-022-01102-x
WHO Classification of Tumours Editorial Board. (2020). Female genital tumours (5th ed., Vol. 4). International Agency for Research on Cancer.
Yano, M., Ito, K., Yabuno, A., Ogane, N., Katoh, T., Miyazawa, M., Miyazawa, M., Hasegawa, K., Narahara, H., & Yasuda, M. (2019). Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma. Modern Pathology, 32(7), 1023–1031. https://doi.org/10.1038/s41379-019-0220-1
Zhu, B., Gu, H., Mao, Z., Beeraka, N. M., Zhao, X., Anand, M. P., Zheng, Y., Zhao, R., Li, S., Manogaran, P., Fan, R., Nikolenko, V. N., Wen, H., Basappa, B., & Liu, J. (2024). Global burden of gynaecological cancers in 2022 and projections to 2050. Journal of Global Health, 14, 04155. https://doi.org/10.7189/JOGH.14.04155
DOI: https://doi.org/10.14421/biomedich.2026.152.1907-1915
Refbacks
- There are currently no refbacks.
Copyright (c) 2026 Amelinda Natania Nurasih, Eviana Norahmawati, Muhammad Luqman Fadli, Diah Prabawati Retnani, Rahmat Sarwo Bekti
Biology, Medicine, & Natural Product Chemistry |
|
